LP-184

Lantern Pharma's HARMONIC trial for LP-300 demonstrated an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with enrollment expanding in Japan and Taiwan where never-smokers represent up to 40% of NSCLC cases.

Lantern Pharma's LP-184 has been granted Fast Track designation by the FDA for treating triple-negative breast cancer, marking its second such designation in 2024.

The FDA granted Fast Track Designation to Lantern Pharma's LP-184 for treating Triple Negative Breast Cancer (TNBC), marking its second Fast Track Designation in 2024.

Lantern Pharma's LP-300 Harmonic Trial demonstrated an 86% clinical benefit rate in initial NSCLC patients, expanding to Japan and Taiwan.

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low/ultra-low breast cancer, potentially expanding treatment options for this patient subgroup.